Pre-Heparin Plasma Lipoprotein Lipase Mass: Correlation With Intra-Abdominal Visceral Fat Accumulation

Abstract

Pre-heparin plasma LPL mass is closely associated with intra-abdominal fat distribution, and the measurement of its value gives useful information concerning metabolic disorder.

Serum lipoprotein lipase mass: Clinical significance of its measurement

“…We and other groups have reported that intra-abdominal visceral fat area assessed by CT at umbilical level had an inverse relationship to LPL mass and activity in PHP [26][27][28]. Similar results were obtained on the association between intra-abdominal visceral fat and pre-heparin LPL mass [19] by recruiting a total of 58 subjects comprising 50 hyperlipidemic and 8 normolipidemic subjects.…”

“…We have shown that plasma LPL mass correlated positively with serum HDL-C level and inversely with serum TG level, but did not significantly correlate with low-density lipoprotein (LDL)-C [19]. Other group in Japan has reported similar results for 377 Japanese individuals who underwent annual health examinations [14].…”

“…It has been reported that serum LPL mass had a positive relation with PHP-LPL mass [14,19,20], although the degree of the relation appeared to differ among the reports. It should be noted that Hirano et al [20] have shown that the delta LPL concentration was strongly related to the PHP-LPL concentration (r =.965, P </=.0001), but not to the serum LPL mass, suggesting that the weak correlation between serum LPL and PHP-LPL levels was attributable to contamination of PHP by pre-existing LPL.…”

“…From the last decade, however, several groups of researchers [12][13][14][15][16][17][18][19] have shown the clinical significance of measuring LPL protein mass in plasma or sera by an enzyme-linked immunosorbent assay (ELISA) without heparin injection (simply put as serum or plasma LPL mass). In earlier studies, researchers applied the measurement of plasma or serum LPL mass to detailed analysis and characterization of type 1 hyperlipidemia (HLP) [16,17].…”

Effect of the Angiotensin II Receptor Antagonist Telmisartan on Lipoprotein Lipase Mass in Preheparin Serum

“…Kobayashi et al 11,55) also reported a link between the increase of visceral fat volume and low preheparin LpL mass concentration. These findings suggest that therapy to reduce visceral fat volume can be expected to lead to an increase of preheparin LpL mass concentration.…”